Purpose: We determined if pharmacological dosages of phosphodiesterase type 5 inhibitors (PDE5) inhibitors were present within a group of natural products marketed for the treatment of erectile dysfunction.
Complementary and alternative medicine (CAM) continues to grow as a form of treatment for a variety of medical conditions. 1 Treatment of urological diseases has a long history of CAM practices. For instance saw palmetto has been used to treat lower urinary tract symptoms (LUTS) for more than a century and remains a top selling herbal preparation. 2 In addition, more than 42% of men with or at risk for prostate cancer use vitamin and mineral supplements. 3 Similarly erectile dysfunction (ED) remains a common societal problem. During the last 7 years the addition of phosphodiesterase type 5 (PDE5) inhibitors to the treatment regimen for men with ED has been nothing less than revolutionary. Sildenafil and related compounds are now the most frequently prescribed drugs for the treatment of ED. 4 Despite unproven efficacy natural products have long been touted as a method of treating ED, with aphrodisiacs having been available for millennia and remaining a significant part of many cultures. 5 Herbal products are treated as foods by regulatory agencies in North America. As such they are not subject to the rigorous validation required for the approval of pharmaceutical agents. Production quality of herbal products has only recently become regulated. As of January 1, 2004 in Canada the Natural Health Products Regulations were enacted and applied to all natural health products. 6 Similar measures are being enacted in Europe as well. 7 The recent scandal surrounding the prostate cancer herbal product PC-SPES highlights this necessary regulatory enforcement. The PC-SPES product, known to induce castrate levels of testosterone and decrease prostate specific antigen levels, 8 was later discovered to contain pharmacological dosages of diethylstilbestrol, 9 indomethacin 8 and warfarin. 8, 10 Given the size of the market for ED drugs, it is not surprising that many marketed herbal products for ED claim to have efficacy similar to that of PDE5 inhibitors without side effects or need for medical assessment. Given the history of some herbal products containing pharmacological agents, we determined whether herbal ED products contain PDE5 inhibitors.
MATERIALS AND METHODS
Product procurement. We purchased 7 brands of marketed herbal products for the treatment of ED. Purchases were limited to oral tablets or capsules. Teas, tonics and foods were excluded from this analysis. Purchases were also limited to products with claims of efficacy if taken before sexual activity and not on a routine basis. Of the brands 6 were purchased via the Internet and 1 via a local health food specialty store. The Appendix lists the names and web sites of the tested preparations.
Product handling and shipping. Twelve tablets or capsules were removed from the original bottle, placed into a light shielded plastic container and assigned a study letter (A through G) by 1 of the study investigators (MH). Products were then shipped at room temperature to the Prostate Cen- † Financial interest and/or other relationship with Bio-Advantex Pharma, Chiron, Astra Zeneca, Adventis, Novartis and GlaxoSmithKline.
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tre at Vancouver General Hospital for high performance liquid chromatography analyses. Standards of PDE5 inhibitors for sildenafil, tadalafil and vardenafil were commercial pharmaceutical tablets.
Sample preparation. Each of the 7 herbal preparations was emptied from the capsules or tablets, crushed and transferred into 13 ϫ 100 mm Pyrex ® screw cap tubes, and weights determined. Standards for sildenafil were tablet samples of Viagra ® (Pfizer Inc, 50 mg, Lot 2144), and for tadalafil and vardenafil tablets of Cialis ® (Lilly, 20 mg, Lot A020228) and Levitra ® (Bayer, 10 mg, Lot BXB7FT1), respectively. Standards were similarly transferred to Pyrex ® tubes. Samples and standards were extracted with 5 ml of 50% reagent ethanol (Fisher Scientific A962-4) by vortexing until contents were fully disaggregated followed by sonication (VWR model 150T) for 30 minutes at room temperature. Aliquots of samples and standards were clarified by centrifugation at 10,000 g. Standards were serially diluted in 50% ethanol to bring them into the appropriate linear dynamic range for analysis. Viagra tablets are formulated as sildenafil citrate and values are given as sildenafil citrate equivalents to allow for direct comparison with these commercial products. Samples were diluted 10-fold in 50% ethanol and an initial set run to determine appropriate further dilutions.
High performance liquid chromatography-mass spectrometry. A Waters 2695 Separations Module equipped with a Waters/Micromass ZQ2000 ® detector was used for quantitative analyses of sildenafil, tadalafil and vardenafil. The ZQ2000 detector settings for the scan function were capillary 3 kV, desolvation temperature 250C, source temperature 120C and cone temperature 20C. Extractor, RF lens and multiplier voltages were 3, 0.5 and 650 V, respectively, desolvation and cone gas flows were 300 to 50 l per hour, respectively, and cone voltage switched between 20 and 45 V. Scans were 0.5 seconds from 250 to 750 amu in electrospray ionization positive mode. For single ion recording (SIR) functions masses of 390.25, 475.26 and 489.28 with 0.3 seconds dwell, and cone voltages of 20, 45 and 45 V were used for tadalafil, sildenafil and vardenafil, respectively, in electrospray ionization positive mode. These molecular weights reflect the protonated parent molecule. Model and actual isotopic distributions obtained are noted in figures 1 and 2. Other parameters were like those of the scan mode.
Separation was performed using a Waters Nova-Pak ® C18 3.9 ϫ 150 mm 4 m column at 25C. High performance liquid chromatography grade acetonitrile and methanol (Fisher Scientific), and formic acid (EM Science™, Analar grade), were used to prepare the mobile phase for liquid chromatographymass spectrometry. The mobile phase consisted of 0.1% formic acid in Milli-Q ® water (A), acetonitrile (B) and methanol (C) using a 20:10:70 ratio for A-to-B-to-C. Run times were 35 minutes per sample. 
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RESULTS
Retention times for tadalafil, sildenafil and vardenafil were 6.2, 25 and 27 minutes, respectively, and calibrations were run with each sample set. Figure 3 demonstrates the representative chromatograms of all herbal specimens with a sildenafil control. Significant adulteration with sildenafil was noted in sample B (Super-X). Figure 1 , a is the actual sildenafil mass spectrum from the peak at 25 minutes in sample B. Figure 1 , b compares this with the computer generated model of isotopic distribution for sildenafil, definitively identifying the presence of sildenafil in sample B. Measured average sildenafil levels in sample B (Super-X) were 30.2 mg per capsule, ranging from 27.6 to 31.3 (as sildenafil citrate equivalent). Figure 4 demonstrates representative chromatograms of the herbal preparations with a tadalafil control. Significant adulteration with tadalafil was noted in sample F. Figure 2 , a shows an actual tadalafil spectrum from the peak at 6.2 minutes for a 100ϫ dilution of sample F. Figure  2 , b compares this with the computer generated model of isotopic distribution of tadalafil, definitively identifying the presence of tadalafil in sample F. Measured average tadalafil levels in sample F (Stamina-Rx™) were 19.77 mg per tablet ranging from 18.0 to 22.0. Triplicate samples analyzed in duplicate were examined as minimum criteria for each. Duplicate repeatability was 3.0%, 1.7% and 7.1% relative standard deviation for sildenafil, and 4.6%, 4.1% and 4.8% relative standard deviation for tadalafil. Means of the duplicates were used in the calculation of average adulterant levels. Significant levels were not detected in any other samples. Vardenafil was not detectable in any of the samples. Figure 2 , c is the equivalent of figure 2 , b represented as a centroided model. Figure 2 , d has been included to demonstrate the lack of alignment of the standard with the artifact peak observed at 16.4 minutes in sample A from figure 1. The artifact at 16.2 minutes is due to the spillover of the second isotopic peak into the 390.25 amu SIR function used for tadalafil data collection. DISCUSSION The use of CAM practices continues to gain acceptance among the public to treat and palliate a variety of medical conditions. Recent data from Gordon and Lin indicate that CAM practices continue to become increasingly popular. 11 It is important to point out that most CAM practices have not been validated using the principles of medical evidence such as randomized clinical trials, although there seems to be improvement in this area. 1 Given their high prevalence, it is not surprising that many herbal products are being marketed to treat urological conditions. Saw palmetto, an herbal product to treat LUTS, is one of the top selling herbal products and has some evidence of proven efficacy. 2 A randomized study is currently under way assessing this product in comparison to pharmacological agents commonly used to treat LUTS.
ED is a common problem of aging males. As many as 50% to 70% of men 75 years old or older experience some degree of ED and the prevalence of this condition increases with age. 12, 13 The notion of using natural products to treat ED is not new. Aphrodisiacs have been touted in many cultures for thousands of years to improve sexual function and desire. Yohimbine, initially derived from the Corynanthe yohimbe tree, is an example of such a product that has worked its way into the pharmacological industry. 5 During the last 7 years the addition of PDE5 inhibitors to the treatment regimen for men with ED has been nothing less than revolutionary. Sildenafil and related compounds are now the most frequently prescribed drugs for the treatment of ED. 4 Herbal products are treated as foods by regulatory agencies in North America. As such they are not subject to the rigorous validation required for the approval of pharmaceutical agents. Production quality of herbal products has only recently become regulated. As of January 1, 2004, in Canada the Natural Health Products Regulations were enacted and applied to all natural health products. Given the size of the market for ED drugs, it is not surprising that many marketed herbal products for ED claim to have efficacy similar to that of PDE5 inhibitors without side effects or need for medical assessment.
To our knowledge this study represents the first to assess systematically a host of products marketed for the treatment of ED. Of the 7 tested products 2 demonstrated evidence of pharmacological doses of PDE5 inhibitors. Since these are not naturally occurring compounds, one can only conclude that these products have been deliberately contaminated with these agents. These data are also consistent with periodic reports from the Food and Drug Administration. The clinical implications of these data are significant. Fatal interactions with PDE5 inhibitors and commonly consumed drugs have been reported, and are well accepted. For example, use of PDE5 inhibitors and nitrates can lead to hypotension, shock and death. Nitrate usage is generally regarded as an absolute contraindication to PDE5 inhibitor prescription.
14 However, these agents purchased over-the-counter at local stores or via the Internet are touted as safe and devoid of adverse side effects. To our knowledge case reports of fatal interaction with these natural products have not occurred. However, it is possible that they are not being recognized due to the presumed safety of these products. Many spouses may also not be aware that their sexual partners have used these agents.
There are several limitations of this study that deserve mention. We limited our purchases to products that were specifically recommended for use before intercourse on an as needed basis. The majority of marketed products is recommended for daily use and perhaps is not as prevalently contaminated with PDE5 inhibitors. Similarly since we limited our analysis to capsules and tablets, we cannot generalize our findings to other products such as teas, tonics and raw extracts.
CONCLUSIONS
These products require regulation. Many pharmacological raw chemicals are easily purchased overseas, and can be added to any product and marketed as natural and safe. 
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PC-SPES, an herbal preparation touted for the treatment of prostate cancer, was known to induce castrate levels of testosterone and decrease prostate specific antigen levels. 8 PC-SPES had gained tremendous popularity among patients and was being evaluated in randomized trials. Later chemical composition analyses indicated that PC-SPES and its related compound SPES were contaminated with pharmacological dosages of warfarin, 10 diethylstilbestrol 9 and indomethacin. 10 PC-SPES was ultimately withdrawn from the market at the insistence of regulatory agencies. Serious medical complications had been reported from PC-SPES and likely could have been prevented had regulation existed. These data indicate that the same can now be said about certain herbal products used to treat ED.
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